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SUMMARY
Objective: To describe the use and determine the prevalence of off-label and unlicensed 
drug use prescribing in a pediatric intensive care unit in a Southeastern Brazilian hospi-
tal. Methods: Cross-sectional study of inpatients in a pediatric intensive care unit from 
May 2008 through January 2009. The classification according to the Brazilian regulatory 
agency (Agência de Vigilância Sanitária – Anvisa) approval criteria was based on the 
Anvisa electronic package insert list, Pharmaceuticals Dictionary, and the analysis was 
conducted through R software. Results: We analysed 1,054 prescription items for 73 
patients. Females predominated (52%), and the patients’ age ranged from 0 to 16 years. 
Among the prescribed items, 23.4% were off-label, 12.6% were unlicensed, 1.4% were 
both off-label and unlicensed, 86% had at least one item off-label, and 67% had at least 
one unlicensed drug. The most frequently prescribed therapeutic groups were systemic 
anti-bacterial, analgesic, psycholeptic, and antiasmathic agents. Conclusion: The cur-
rent study results confirm the high prevalence of unlicensed and off-label drug use in a 
pediatric intensive care unit.
Keywords: Pediatrics; off-label drug use; drug prescribing; drug package inserts.
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INTRODUCTION
Drug prescribing in Pediatrics follows the same criteria 
adopted for adults, although there are more particulari-
ties and often insu cient evidence to assure risks and 
benefits. Among these criteria, the choice of the appro-
priate drug therapy, dosage, administration, therapy 
length, lack of contraindications, and minimal adverse 
reaction likelihood, as well as established safety and e -
cacy are important aspects in the rational use of drugs1-3.
Nevertheless, in clinical practice, drugs with safety 
and e cacy evidence only in the adult population are 
used and often required in pediatric therapy. In infants, 
drug metabolism and mainly renal function are less ef-
ficient. This means that, disregarding the exceptions, 
the drug effect is longer and an accumulation trend may 
occur1-3.
Pharmacokinetic and pharmacodynamic character-
istics change over a child’s development, and important 
stages, such as drug absorption, distribution, metabo-
lism, and clearance can be inuenced by hydrogen poten-
tial (pH) uctuations, gastrointestinal motility, enzyme 
deficiency, and liver immaturity1,2,4.
Therefore, because of these and other conditions, data 
from drug studies with evidence conducted only in an 
adult population cannot be extrapolated, although, in 
clinical practice, children often undergo therapy using 
these drugs, which sets an off-label or unlicensed use4-7. 
This practice can bring beneficial results, indicating 
new trends for scientific research in standardizing indi-
cations and dosages. On the other hand, it can lead to 
adverse reactions, in addition to no therapeutic effect8-10. 
It is estimated that between 23% and 60% of these drugs 
account for adverse reactions in children10-12.
Currently, the Food and Drug Administration (FDA) 
regulations encouraging children inclusion in clinical re-
search have increased drug safety and e cacy studies in 
children, as well as policies to reduce risks and proposals 
of pharmacovigilance to be implemented over the drug 
life cycle5,13-15.
However, despite the evidence with an improved 
drug standard trend in Pediatrics, there is still little in-
formation about the extension in off-label drug use in 
hospitalized children, the kind of drugs most frequently 
prescribed, and the characteristics of the patients who re-
ceive these drugs16,17.
Literature reports that off-label and unlicensed medi-
cation is more extensively used in newborn and intensive 
care units, with a prevalence up to 90%4,8,13,18-20.
Studies covering this theme are predominantly from 
institutions based in industrialized countries. In Brazil, 
these studies are far less frequent and just a few of them 
evaluate the prevalence of this drug use in intensive care 
units18.
Thus, the current study aimed to determine the preva-
lence of unlicensed and off-label drug use in children due to: 
age/weight, dose/frequency, indication, and administration 
route in children hospitalized in an intensive care unit (ICU).
METHODS
Cross-sectional study conducted at the pediatric ICU in 
a hospital in Belo Horizonte, Brazil, from May 2008 to 
January 2009. This study was approved by the Hospital Re-
search Ethics Committee (CAAE: 0010.0.191.000-08).
The study population consisted of all patients admitted 
to the pediatric ICU having at least one drug prescribed 
in each one of the evaluation days over the study period. 
Volume replacement âuids, parenteral nutrition solutions, 
blood product transfusions, and supplemental oxygen 
were not considered medication, as in another study18.
For sample calculation, the EpiInfo software version 
6.04 with a maximum acceptable variation of 5% was used, 
achieving an estimated sample of 73 patients. Statistical 
analysis was conducted in R software, and the variables 
included patients’ age, gender, weight, and all medications 
prescribed with respective formulation, doses, frequen-
cies, indications, and administration routes.
The adopted criterion for medication adequacy pre-
scribing was based on the approval classification by the 
Agência Nacional de Vigilância Sanitária (Anvisa), having 
the Anvisa package insert list and the 2009 Pharmaceuti-
cals Dictionary as references. The Anatomical Therapeu-
tic Chemical Classification (ATC) adopted by the World 
Health Organization to fit every kind of drug according to 
its action in organs or systems and its chemical, pharma-
cologic, and therapeutic properties was used.
Each drug was evaluated as off-label or unlicensed 
based on the product license information. The following 
drugs were considered unlicensed: 1) those contraindicat-
ed for children; 2) extemporaneous formulations prepared 
or manufactured in the hospital; 3) drugs whose safety and 
eâ cacy in the pediatric population has not been set yet; 
4) drugs not marketed in Brazil. In off-label category, all 
drugs in which the prescription showed a discrepancy be-
tween the product license information for indication, age 
(or weight), dose (or frequency), and route of administra-
tion were considered. A few of them were classified after 
more than one reason is found.
Figure 1 shows the âowchart proposed in this study for 
analysis and classification of prescription items.
The prevalence was defined as the number of individu-
als receiving at least one off-label and/or unlicensed drug 
prescription per 100 hospitalized children. The prevalence 
rate was stratified by age and gender. Fisher’s exact test was 
used to compare the prevalence of prescriptions between 
gender and age, and p-values < 0.05 were considered sig-
nificant in all statistical analysis.
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Does the drug have 
any marketing 
authorization 
in Brazil or is it 
imported?
Is the drug 
contraindicated for 
the pediatric group?
Was 
extemporaneous 
formulation required 
to facilitate the 
administration 
in the child?
Is there lack of data 
on safety and efcacy in 
pediatric population?
Yes
Unlicensed drug Approved use
No
Are there any use 
restrictions or 
contraindications regarding 
a special pediatric age 
group?
Was the drug
 used out of the
 recommended dose, 
indication, administration 
route, and/or age found in 
the package insert?
Yes
Off label Approved use
No
and/or
and/or
and/or
Figure 1 – Flowchart representing the analysis and classiﬁ-
cation of prescription items.
RESULTS
We recorded 1,054 prescription items, involving 117 dif-
ferent drugs, with a mean of 14 items per patient.
The study data was based on prescriptions for 73 pa-
tients, corresponding to 100% of the sample calculation. 
The age ranged from zero to 16 years, with a 47.9-month 
median (equivalent to approximately four years), and most 
subjects (52%) were female. The most frequent admission 
motives were respiratory (39%), neurologic (16%), and 
gastrointestinal (12%) diseases.
The most frequently prescribed therapeutic groups ac-
cording to the ATC second level of classification were sys-
temic anti-bacterial agents (20.3%), followed by analgesic 
(17%), psycholeptic (8.5%), antiasmathic (6.3%), and antac-
id, as well as drugs to treat peptic ulcer and atulence (5.5%).
Out of 1,054 prescription items, 62.5% were observed 
to be approved drugs, 23.4% had an off-label use, 12.6% 
an unlicensed use, and 1.4% were classified as having both 
off-label and unlicensed use. Out of the 73 patients, 86% 
were given at least one drug with an off-label use, and 
67% at least one unlicensed use drug.
Figure 2 illustrates the 21 drugs with the highest pre-
scription frequency, considering either approved use or 
off-label and unlicensed use, with the classification rea-
sons. The most frequently prescribed drug was sodium 
dipyrone (73 times), which in 35 cases (47.9%) was pre-
scribed as approved and in 38 episodes (52.1%)  as an 
off-label use.
According to the reasons for the classification as off-
label use, the most frequent was dosage, followed by age 
and route of administration. Regarding the unlicensed 
drugs, the most frequent reason was “safety and e cacy 
not established”, followed by drugs not marketed in Brazil 
and drugs contraindicated for pediatric use.
In the setting of prescribing drugs per gender, 51% of 
the off-label and unlicensed drugs were prescribed for fe-
males and 49% for males.
The patients’ age was categorized into three groups ac-
cording to the age ranges: from 0 to < 2 years, from 2 to 
12 years, and > 12 years of age. Table 1 shows the descrip-
tion and comparison of prescribing drugs by age group. 
Among all patients who were prescribed at least one off-
label drug, 83.3% were aged < 2 years.
The most frequently prescribed off-label therapeutic 
groups, according to the ATC second level of classifica-
tion, were analgesic (33%) and systemic anti-bacterial 
(25%) agents. The most frequently unlicensed drugs were 
analgesic and antacid (29%) agents and medication to treat 
peptic ulcer and atulence (21%).
DISCUSSION
In a hospital in Porto Alegre, 747 prescription items were 
analyzed and a prevalence of 49.5% was found for off-la-
bel drug use and 10.5% for unlicensed drugs in the pe-
diatric ICU18. Shah et al.16, over a year, demonstrated ap-
proximately 78% of the children were given at least one 
off-label drug, thus raising the medication cost in Ameri-
can hospitals. In a Swiss hospital, the prevalence of 25% 
for off-label drug use and 24% for unlicensed drugs were 
recorded, based on an analysis of 483 prescriptions8. The 
current study evaluated 1,054 prescription items and dem-
onstrated a prevalence of 23.4 and 12.6% for off-label and 
unlicensed drug use, respectively.
Aiming to avoid unnecessary procedures and shorten 
the length of stay in hospitals, this practice is considered 
common in a pediatric ICU setting, as the patients are 
critically ill, although no relationship of the prevalence of 
these drugs with the disease severity has been found in a 
study conducted in Brazil18.
The information on dosage/frequency indicated is 
widely varied in each pediatric population subgroup, high-
lighting the need for consensus among countries21-23. One 
example is fenoterol, unlicensed in the United Kingdom, 
but authorized in Brazil for children aged > 2 years in the 
treatment of asthma. Sodium dypirone is another example 
of drug that was not approved by the FDA because se-
vere cases of agranulocytosis occurred in the 70s, but it is 
widely used and licensed in Brazil and in other parts of the 
world11,13,17. Even with the differences from one country to 
another, when this study results are compared with studies 
using other methods, the results found were similar.
and/or
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Aminophylline
Epinephrine
Ketamine
Dopamine
Fenoterol
Ferrous sulfate
Domperidone
Furosemide
Dobutamine
Insuline
Multivitamin product
Caffeine citrate
Phenobarbital
Ranitidine
Morphine
Vitamin K
Ampicillin
Gentamicin
Fentanyl
Midazolan
Dipyrone
Safety and efﬁcacy not established Contraindicated for pediatric patients
Dose Age
Not marketed in Brazil Extemporaneous formulation
Route
70 60 50 40 30 20 10 0 10 20 30 40 50
Age and route
Figure 2 – Most frequently prescribed drugs per classiﬁcation (approved and off-label or unlicensed drugs) and respective 
reasons.
In addition, there are differences between pharmaceu-
tical formulations and commercially available doses, as is 
the case of injectable acetaminophen that is not available 
in Brazil, and hydrochlorothiazide, captopril, and loraz-
epam, which are not available in low doses or in oral liquid 
pharmaceutical formulations22,24.
In the current study, extemporaneous formulations 
did not have a high prevalence (2%), but in 100% of drugs 
in which they were prescribed (hydrochlorothiazide, 
captopril, lorazepam), the extemporaneous formulations 
were prepared from capsules or tablets due to the di -
culty or inability of patients to swallow and the need for 
Condition
Age (years)
p-value0 - < 2 2-12 > 12
n % n % n %
Approved drugs 1 20.0 1 20.0 3 60.0 < 0.001*
Only off-label drugs 15 83.3 3 16.7 0 0.0  
Only unlicensed drugs 0 0.0 3 60.0 2 40.0  
Both off-label and unlicensed 30 66.6 8 17.8 7 15.6  
*Fisher exact test.
Table 1 – Description of drug prescription per age group
Approved use drugs Off-label or unlicensed use
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lower doses. Captopril, for example, is used to treat heart 
failure in children and licensed only as tablets, leaving 
no other more appropriate alternatives in prescribing22,24.
The absence of pediatric formulations leads to a com-
plex calculation to use the appropriate dosage, and dam-
ages are plentiful, from the financial losses associated 
with drug waste to the absence of information on bio-
availability, physicochemical and microbiological stabil-
ity due to the lack of an effective therapy22,23,25,26.
Only hospital pharmacies with an appropriate quality 
control infrastructure and qualified professionals to per-
form timely assays to meet the urgency of clinical therapy 
in an ICU will produce effective and safe medicines25,26.
In the current study, the highest prevalence of off-
label drug prescribing occurred because of the dose, 
mostly among anti-bacterial and analgesic agents, as 
seen in other studies6,17,18,19.
Sodium ampicillin, a semi-synthetic beta-lactam an-
tibiotic derived from the penicillins, was administered 
in a higher dose than that licensed (25 to 50 mg/kg/day 
divided q6-8h; total of 150 mg/kg). This is not always in-
appropriate, as sodium ampicillin is often prescribed for 
severe pneumonia in children, with higher doses recom-
mended, in addition to bacterial meningitis when higher 
serum levels are required6,27.
Sodium dipyrone, on the contrary, was administered 
in a few cases in lower doses compared with the prod-
uct license (children with 16 to 23 kg, 0.3-0.8 mL IV; 
0.1 mL prescribed). This can lead to uncontrolled anal-
gesia and fever. There were also cases in which IV so-
dium dipyrone was prescribed for children under 1 year 
old. According to the license, if parenteral administra-
tion is considered in infants between 3 and 11 months 
of age, only the intramuscular rout should be used. The 
parenteral route is associated with a high risk of anaphy-
lactic reactions, and this must be considered28.
As for unlicensed drugs, the highest prevalence has 
to do with “safety and e cacy not stablished” present in 
the drug package inserts, with morphine sulfate, a drug 
acting on the nervous system, being the most frequently 
prescribed drug within this criterion, as found by other 
authors8,14,17. This stresses the need for further trials in-
volving children, particularly of drugs frequently used 
in the hospital routine, which have been used for a long 
time, to ensure that prescriptions are based on safety and 
e cacy evidence, as well as an increase in the availability 
of more exible and appropriate pharmaceutical formu-
lations for the age group6,9,17,23.
Ranitidine hydrochloride, a drug used to treat gas-
troesophageal reux in children, is an H2 histamine 
receptor antagonist having high selectivity and rapid 
action onset, which inhibits basal and stimulated acid 
secretion, reducing both acid volume and content and 
pepsin secretion; it is commercially available as inject-
able, tablet, and syrup formulations28. In this study, the 
injectable formulation was prescribed for one-year-old 
infants, but in these cases only the syrup formulation has 
no contraindication regarding the age group.
In a study conducted in Italy, caffeine citrate, a drug 
used to treat apnea in premature infants, is unlicensed 
in that country and, therefore, among the unlicensed 
drugs, it was one of the most frequently used, as oc-
curred in the present study. In Brazil, it is marketed only 
in combination with analgesic drugs and has no license 
as a monodrug19,22. This underlines the need for other 
pharmaceutical formulations in the Brazilian market, 
mostly for drugs frequently used in hospital routine. For 
treatment of neonatal apnea, the licensed drug for this 
indication in Brazil is aminophylline, although lower 
dose formulations for a safe administration in neonates, 
mainly those with low birth weight, and also in order 
to avoid waste are not available6,22. Caffeine citrate has 
lower toxicity and is licensed in the United States and 
other countries16.
Regarding the ICU setting, a few drugs have little 
therapeutic relevance, but if the disease severity is 
considered, a longer exposure to drugs, particularly of 
newborns during the critical phase of development and 
immaturity of organs, makes them more vulnerable to 
adverse reactions, increasing the risk of sequelae and the 
need for other interventions during or after the treat-
ment 5,9,19.
Regarding the gender of patients, no statistically sig-
nificant difference was found (p-value = 1.000)1, indicat-
ing that gender is not associated with either the off-label 
or unlicensed drug prescription. Considering the age 
group, an association between the prescription condition 
and the patient’s age was observed (p < 0.001), with high 
prevalence of off-label drugs in infants aged up to 2 years, 
similarly to other studies in which the authors highlight 
the high prevalence of this drug use mainly in neonates, 
possibly due to the lack of appropriate formulations and 
alternatives meeting this age group requirements18,19.
The study data was obtained from patients’ medical 
records and this is one of the main limitations in the 
present study. The di culties included prescription era-
sure, lack of data on disease history, and incomplete data 
in the patient’s medication.
CONCLUSION
The results of the current study confirm the high preva-
lence of off-label and unlicensed use of drugs in Brazil, 
show the different prescription habits in Pediatrics and 
reveal drug classes requiring regularization and research 
incentive assuring e cacy and safety, thus contributing 
to the promotion of rational drug use in Pediatrics.
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Off-label and unlicensed drug use in pediatric in-
tensive care units is an ethical dilemma considering risk 
and benefit. The mentioned drugs are widely used and 
have proved therapeutic e cacy, although with a few 
limitations, mainly in patients aged < 2 years who were 
predominantly exposed.
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